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Aims Introduction
Results
• Know in a general way which is the immunologic response when a tumour appears.
• Define what natural killer T cells are and their cellular characteristics.
• Describe why invariant natural killer T cells would be effective as anti-tumour therapy
• Scientific literature search in Pubmed database using as key words: NKT cells or natural killer T
cells, iNKT cells or invariant natural killer T cells, tumour immunology and cancer/ tumour
therapy. Papers were selected for: quality, date of publication and journal impact.
• Search in official websites of World Health Organization and Clinical Trials.
Cancer is a disease that can affect any part of the body. One defining feature of it is the rapid
creation of abnormal cells that grow beyond their usual limits, and which can then invade
adjoining tissues and spread to other organs.
It is one of the most important diseases nowadays because is a leading cause of death
worldwide. The research of new therapies is crucial for helping patients that do not respond to
classical therapies such as radiotherapy, surgery or chemotherapy.
It is known that our immune system is able to fight against tumours in a process referred to as
cancer immunoediting which involves three phases: elimination, equilibrium and escape.
Because of it many immunotherapies are being set to treat tumours. For example, here we
describe NKT cells and their demonstrated anti-tumour potential.
Materials and Methods
Characterization of NKT cells iNKT cells for Cancer Treatment
1. What are NKT cells? NKT cells are a unique subset of lymphocytes that express at the
same time NK cell markers (NK1.1 in mice and CD161 in humans) as well as a TCR α/β, with a
restricted repertoire. This TCR recognizes glycolipids presented by CD1d, a non-classical antigen
presenting molecule that associates with β2-microglobulin. The rapid response of this cells to
their antigens is characteristic of an innate immune response, and allows the polarizing cytokines
(IFN-γ and/or IL-4) to regulate adaptive immunity.
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1. Mechanisms to attack tumour cells
•iNKT cells express high
levels of granzyme,
perforin and FasL that can
produce cytolysis or
ligand induced killing of
tumour cells.
Direct
•iNKT cells produce large
amounts of IFN-γ, which
activates NK cells and
CD8+ T cells that have
cytotoxic activity on
tumour cells.
Indirect
Figure 2. Anti-tumour immune responses induced by activated
iNKT cells. After activation, iNKT cells exert direct anti-tumour
activity, including perforin, granzyme and Fas ligand, and up-
regulate CD40L which stimulates CD40 on DC to produce IL-12.
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4. Activation
Two pathways:
 Activation mediated by cytokines
 Antigenic activation by TCR signal
• Direct: APCs presentation to NKT cells by
CD1d-glycolipid antigen complexes.
• Indirect: APCs are activated through their
TLRs that trigger the loading of CD1d
molecules with endogenous antigens
presented to NKT cells.
6. NKT cells in Regulation of Tumour Immunity
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2. Manipulating iNKT cells for Cancer Immunotherapy
 Stimulating patient’s own iNKT cells by the administration of exogenous activators
• IL-12  this cytokine exerts multiple anti-tumour effects that include the activation of NK, iNKT and T
cells in addition to its immune-cell-independent anti-angiogenic effects to mediate tumour rejection.
• α-GalCer  iNKT cells recognize it in conjunction to CD1d. After activation these cells exert potent direct
and indirect anti-tumour activities, inducing the production of large amounts of cytokines (IL-12 and IFN-γ).
• α-GalCer-DCs  the adoptive transfer of α-GalCer-pulsed DCs induce more potent anti-tumour effects
than the treatment with soluble α-GalCer.
 Transferring activated iNKT cells to the patient
• in vitro activated iNKT cells  iNKT cell populations are isolated from a patient with cancer,
selected and expanded in vitro with cytokines before being infused back into the patient. These expanded
iNKT cell populations can be co-infused with CD1d ligand-pulsed DCs to enhance the anti-tumour activity in
vivo.
• iPS-derived iNKT cells  for patients whose NKT cells are limited, induced pluripotent stem cells can
be generated , developed into functional iNKT cells in vitro and then injected to the patient. This cells have
demonstrated to suppress tumour growth in vivo.
3. Clinical trials done with this therapy
According to ClinicalTrials.gov nowadays there are 138 studies working with NKT cells to treat
cancer around the world.
Conclusions
• NKT cells express NK cell markers and at the same time TCRs α/β with a restricted repertoire that
recognizes CD1d. They can be divided then into three subsets: type I NKT cells (or iNKT cells), type II
NKT cells and NKT-like cells. Once these cells become activated by endogenous or exogenous ligands,
they mediate immunoregulatory functions in different diseases such as cancer. In this case, type I NKT
cells potentiate the anti-tumour response, while type II NKT cells suppress this response.
• iNKT cells, characterized by its semi-invariant TCR and by its specific recognition of α-GalCer
presented by CD1d, can attack the tumour by indirect mechanisms (releasing cytokines like IFN-γ that
activate other effector cells as NK cells or CTLs) or direct mechanisms (by their own cytotoxic
activities).
• To use iNKT cells for cancer treatment we can stimulate the patient's own cells with the
administration of exogenous activators (IL-12 or α-GalCer) or we can transfer in vitro activated iNKT
cells to the patient.
• By the moment, there are a lot of clinical trials and research groups working on this promising new
therapy with iNKT cells, so it is to hope that their optimal and safe therapeutic use will be as rapidly
and efficiently defined as have been defined their various roles and activities and we hope too that
iNKT-cell based immunotherapies in combination or not with other standard therapies could be
established in the near future.
Large amounts of IFN-γ secreted by iNKT cells induce NK cells and
CD8+ T cells to exert indirect anti-tumour responses.
Figure 3.  Map showing where clinical trials with NKT cells to treat cancer 
are being done. 
https://clinicaltrials.gov/ct2/results/map?term=%22natural+killer+T+cells%22+AND+%22cancer%22 
Figure 1. Schematic view of the interaction between the TCR of a NKT cell
and the CD1d molecule presenting a glycolipid antigen.
These are being done with patients with
hematological cancers which usually
express CD1d and also with solid
tumours that do not express CD1d due
to the ability of iNKT cells to attack both
types of cancers.
Some of the results show that the
therapy is safe, generates iNKT cell-
specific responses and have
immunomodulatory effects in cancer
patients.
